David Thomas

Washington, United States
David is currently Vice President, Industry Research at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.
Speaking In
3:00 PM - 4:30 PM
Monday, June 3
As companies face the need to discover or acquire future drivers of value, R&D is both challenging…
103ABC, Level 100
11:00 AM - 12:15 PM
Wednesday, June 5
Emerging company investment for drug development in highly prevalent chronic diseases is shown to…
12:15 PM - 1:30 PM
Wednesday, June 5
After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of…
113ABC, Level 100